Lung Cancer
Volume 45 , Pages S49-S54 , August 2004

Prognostic factors in malignant mesothelioma

  • Jacobus A Burgers

      Affiliations

    • Department of Thoracic Oncology, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-5122958; fax: +31-20-5122572.
    • ,
  • Ronald A.M Damhuis

      Affiliations

    • Rotterdam Cancer Registry, Rotterdam, The Netherlands

References 

  1. Edwards JG, Abrams KR, Leverment JN. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735
  2. Curran D, Sahmoud T, Therasse P. Prognostic factors in patients with pleural mesothelioma: the European Organisation for research and treatment of cancer experience. J. Clin. Oncol. 1998;16:145–152
  3. Gospodarowitcz MK, Henson DE, Hutter RVP, Prognostic factors in cancer. 2nd ed. New York: John Wiley & Sons, Inc.; 2001.
  4. Herndon JE, Green MR, Chahinian AP. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–731
  5. Steele JP. Prognostic factors in mesothelioma. Semin. Oncol. 2002;29:36–40
  6. Metintas M, Metintas S, Ucgun I. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir. Med. 2001;95:829–835
  7. Thylen A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001;92:1224–1230
  8. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 1999;68:1799–1804
  9. Boutin C, Rey F, Gouvernet J. Malignant mesothelioma: prognostic factors in a series of 125 patients studied from 1973 to 1987. Bull. Acad. Natl. Med. 1992;176:105–114 discussion 115–117
  10. Sugarbaker DJ, Flores RM, Jaklitsch MT. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 1999;117:54–63 discussion 63–65
  11. Tammilehto L, Kivisaari L, Salminen US. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients. Lung Cancer. 1995;12:25–34
  12. Pass HI, Temeck BK, Kranda K. Preoperative tumour volume is associated with outcome in malignant pleural mesotheliom. J. Thorac. Cardiov. Surg. 1998;155:310–317 discussion 317–318
  13. Johansson L, Linden CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest. 1996;109:109–114
  14. Ceresoli GL, Locati LD, Ferreri AJ. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;34:279–287
  15. Merritt N, Blewett CJ, Miller JD. Survival after conservative (palliative) management of pleural malignant mesothelioma. J. Surg. Oncol. 2001;78:171–174
  16. British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001;56:250–65.
  17. Takagi K, Tsuchiya R, Watanabe Y. Surgical approach to pleural diffuse mesothelioma in Japan. Lung Cancer. 2001;31:57–65
  18. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int. J. Cancer. 1988;41:525–530
  19. Tiainen M, Tammilehto L, Rautonen J. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br. J. Cancer. 1989;60:618–626
  20. Pyrhonen S, Laasonen A, Tammilehto L. Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma. Eur. J. Cancer. 1991;27:197–200
  21. Isobe H, Sridhar KS, Doria R. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cytometry. 1995;19:86–91
  22. Beer TW, Carr NJ, Whittaker MA. Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma. Ann. Diagn. Pathol. 2000;4:143–148
  23. Emri S, Akbulut H, Zorlu F. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer. 2001;33:109–114
  24. Kahlos K, Soini Y, Paakko P. Proliferation, apoptosis, and manganese superoxide dismutase in malignant mesothelioma. Int. J. Cancer. 2000;88:37–43
  25. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology. 2001;38:535–541
  26. Bongiovanni M, Cassoni P, De Giuli P. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer. 2001;92:1245–1250
  27. Leonardo E, Zanconati F, Bonifacio D. Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma. Pathol. Res. Pract. 2001;197:253–256
  28. Isik R, Metintas M, Gibbs AR. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. Respir. Med. 2001;95:588–593
  29. Di Muzio M, Spoletini L, Strizzi L. Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma. Hum. Pathol. 2000;31:1341–1345
  30. Edwards JG, Cox G, Andi A. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br. J. Cancer. 2001;85:863–868
  31. Ohta Y, Shridhar V, Bright RK. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer. 1999;81:54–61
  32. Kumar-Singh S, Jacobs W, Dhaene K. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J. Pathol. 1998;186:300–305
  33. Kumar-Singh S, Weyler J, Martin MJ. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 1999;189:72–78
  34. Dazzi H, Hasleton PS, Thatcher N. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br. J. Cancer. 1990;61:924–926
  35. Ohta Y, Shridhar V, Kalemkerian GP. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer. 1999;85:2570–2576
  36. Kahlos K, Soini Y, Sormunen R. Expression and prognostic significance of catalase in malignant mesothelioma. Cancer. 2001;91:1349–1357
  37. Benard F, Sterman D, Smith RJ. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J. Nucl. Med. 1999;40:1241–1245
  38. Procopio A, Strizzi L, Vianale G. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer. 2000;29:173–179
  39. Schouwink H, Korse CM, Bonfrer JM. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 1999;25:25–32

PII: S0169-5002(04)00172-2

doi: 10.1016/j.lungcan.2004.04.012

Lung Cancer
Volume 45 , Pages S49-S54 , August 2004

Article Tools